Abstract
Background & Aim With the increase in the number of COVID-19 infections, global health is facing insufficient sources; this study aimed to provide additional data regarding the clinical characteristics of patients diagnosed with COVID-19 and in particular to analyze the factors associated with disease severity, unimprovement and mortality.
Methods 82 studies were included in the present meta-analysis that all of them have been published before May 1, 2020 and were found by searching through the databases Scopus and MEDLINE. The selected papers were studied and analyzed by employing the version 14 of stata software. It should be noted that, we employed I2 statistics for testing and verifying heterogeneity.
Results 82 papers were finally chosen for this meta-analysis, including 74855 infected patients (35673 men, 31140 women). The mean age of the patients was 56.49. The results indicate the prevalence of fever 79.84 (95% CI: 75.22-84.13), cough 59.53 (95% CI: 55.35-63.65), fatigue or myalgia 33.46 (95% CI: 28.68-38.40), dyspnea 31.48 (95% CI: 25.75-37.49) and diarrhea 10.71 (95% CI: 8.20-13.49). The prevalence of the most common comorbidities were hypertension 25.10 (95% CI: 19.91-30.64), diabetes 13.48 (95% CI: 10.61-16.62), cardiovascular diseases 8.94 (95% CI: 6.99-11.10), and chronic kidney disease 3.27 (95% CI: 2.22-4.47).
Conclusion The results of this study are seriously needed to effectively monitor the health of people with comorbidities (hypertension, diabetes, cardiovascular and cerebrovascular disease, coronary heart disease, and chronic kidney disease) to prevent the development of COVID-19 infection.
Highlights
The most prevalent risk factors among patients with COVID-19 were hypertension, diabetes, cardiovascular disease, and chronic kidney disease.
The most common symptoms among individuals who had COVID-19 infection were fever, cough, fatigue or myalgia, dyspnea, and diarrhea.
The mean age of the patients with COVID-19 infection was 56.49.
If the patient is an elderly male with underlying diseases, he is more likely to have severe disorders or even face to death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ethics committee of Shahid Beheshti University of Medical Sciences
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
available
Abbreviations
- WHO
- World Health Organization
- ICU
- intensive care unit
- ACE2
- angiotensin-converting enzyme 2
- No
- Number
